ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Assessment of systemic inflammatory and immune biomarkers and alterations in calcium and parathyroid hormone in hemodialysis patients with type 2 diabetes mellitus
Abstract
Aims: Chronic systemic inflammation and mineral metabolism disturbances are prevalent in hemodialysis patients. The presence of Type 2 Diabetes Mellitus (T2DM) may further exacerbate inflammatory burden and disrupt calcium-parathyroid hormone (Ca-PTH) homeostasis. This study aimed to assess systemic and immune-inflammatory indices together with Ca-PTH levels in hemodialysis patients with T2DM.
Methods: This retrospective multicenter study included 211 maintenance hemodialysis patients, including 97 with T2DM and 114 without diabetes. Inflammatory and immune-related indices, including the PIV, SIRI, SII, NLR, PLR, LMR, NMR, MPVLR, MHR, SII/albumin ratio, and CRP/albumin ratio were evaluated together with hematological parameters, biochemical markers, and mineral metabolism parameters.
Results: Hemodialysis patients with T2DM demonstrated notably elevated concentrations of SIRI, PIV, MHR, IMA, and monocytes compared to their non-diabetic counterparts (p<0.05). ROC analysis showed modest discriminatory performance for SIRI (AUC=0.586) and PIV (AUC=0.583), with PIV demonstrating 71% sensitivity at a cut-off value of 25.28. In contrast, serum calcium and PTH levels were significantly lower in the T2DM, with calcium emerging as the strongest negative predictor. SIRI and PIV were positively associated with leukocyte-related inflammatory markers, whereas calcium and PTH correlated with hemoglobin, hematocrit, albumin, and phosphorus.
Conclusion: T2DM in hemodialysis patients is marked by intensified systemic inflammatory burden and suppression of the Ca-PTH axis. Reduced calcium and PTH levels may reflect disturbances in mineral metabolism and a predisposition to adynamic bone disease. These findings underscore the value of integrating inflammatory indices with Ca–PTH parameters to better elucidate diabetes-associated inflammatory burden and mineral metabolism disturbances in hemodialysis patients.

Keywords : Diabetes, hemodialysis, systemic inflammatory and immune indices, PTH, calcium, mineral metabolism

Download Article


1. Al-Ghamdi SMG, Bieber B, AlRukhaimi M, et al. Diabetes prevalence, treatment, control, and outcomes among hemodialysis patients in the Gulf Cooperation Council countries. Kidney Int Rep. 2022;7(5):1093-1102. doi:10.1016/j.ekir.2022.02.012.
2. Drechsler C, Krane V, Ritz E, März W, Wanner C. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation. 2009;120(24):2421-2428. doi:10.1161/CIRCULATIONAHA.109.857268
3. Ilyas D, Blackburn E, Herbert A, et al. #2866 The CompAct-HD trial reports a persistent inflammatory profile in patients undergoing haemodialysis, acutely exacerbated with each treatment. Nephrol Dial Transplant. 2024;39(Supplement_1):gfae069-0159-2866. doi:10.1093/ndt/gfae069.159
4. Campo S, Lacquaniti A, Trombetta D, Smeriglio A, Monardo P. Immune system dysfunction and inflammation in hemodialysis patients: two sides of the same coin. J Clin Med. 2022;11(13):3759. doi:10.3390/jcm11133759
5. Dawood A, Fiedler R, Markau S, Girndt M, Ulrich C. Polysome profiling proves impaired IL-10 and caspase-8 translation in PBMCs of hemodialysis patients. Biomolecules. 2025;15(3):335. doi:10.3390/biom15030335
6. Xiang F, Sun L, Cao X, et al. CD73 as a T cell dysfunction marker predicting cardiovascular and infection events in patients undergoing hemodialysis. Clin Chim Acta. 2024;555:117791. doi:10.1016/j.cca.2024.117791
7. Diaz-Ricart M, Torramade-Moix S, Pascual G, et al. Endothelial damage, inflammation and immunity in chronic kidney disease. Toxins (Basel). 2020;12(6):361. doi:10.3390/toxins12060361
8. Cecerska-Heryc E, Engwert W, Michalów J, et al. Oxidative stress markers and inflammation in type 1 and 2 diabetes are affected by BMI, treatment type, and complications. Sci Rep. 2025;15(1):23605. doi:10.1038/s41598-025-05818-z
9. Evenepoel P, Stenvinkel P, Shanahan C, Pacifici R. Inflammation and gut dysbiosis as drivers of CKD-MBD. Nat Rev Nephrol. 2023;19(10):646-657. doi:10.1038/s41581-023-00736-7
10. Dempster DW, Evenepoel P, Nickolas TL, et al. Osteoporosis and CKD-metabolic bone disease under the same umbrella: insights from a joint scientific symposium. Kidney Int Rep. 2026;11(5):106362. doi:10.1016/j.ekir.2026.106362
11. Zhang Z, Zhao L, Zhou X, Meng X, Zhou X. Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets. Front Immunol. 2023;13:1098725. doi:10.3389/fimmu.2022.1098725
12. Zhu J, Shi R, Li X, et al. Association between neutrophil percentage-to-albumin ratio and mortality in hemodialysis patients: insights from a prospective cohort study. BMC Nephrol. 2025;26(1):112. doi:10.1186/s12882-025-04027-0
13. Yang W, Zhong Y, Zhou P, Lu D. Monocyte to high-density lipoprotein cholesterol ratio as a marker of the presence and progression of diabetic kidney disease. Ren Fail. 2025;47(1):2438846. doi:10.1080/0886022X.2024.2438846
14. Arıkan FB, Öztürk H. Inflammatory indices in hypertensive hemodialysis patients: clinical implications of MPV and MPVLR. J Med Palliat Care. 2025;6(5):569-574. doi:10.47582/jompac.1773774
15. Arıkan FB, Sağsöz N. Enhancing diagnostic accuracy in polycystic ovary syndrome using novel inflammatory indices. Kırıkkale Uni Med J. 2025;27(2):217-224. doi:10.24938/kutfd.1718713
16. Chen Y, Men K, Meng CM, Ma J, Guo JC. Changes in TLR-4 expression level and CD14+CD16+ monocyte ratio in the peripheral blood of patients with early diabetic nephropathies. ScienceAsia. 2020;46(2):206-212. doi:10.2306/scienceasia1513-1874.2020.022
17. Trandafir MF, Savu OI, Gheorghiu M. The complex immunological alterations in patients with type 2 diabetes mellitus on hemodialysis. J Clin Med. 2024;13(13):3687. doi:10.3390/jcm13133687
18. Jin X, Liu L, Zhang Y, et al. Advanced glycation end products enhance murine monocyte proliferation in bone marrow and prime them into an inflammatory phenotype through MAPK signaling. J Diabetes Res. 2018;2018:2527406. doi:10.1155/2018/2527406
19. Netea MG, Domínguez-Andrés J, Barreiro LB, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020; 20(6):375-388. doi:10.1038/s41577-020-0285-6
20. Bekkering S, Arts RJW, Novakovic B, et al. Metabolic induction of trained immunity through the mevalonate pathway. Cell. 2018;172(1-2): 135-146.e9. doi:10.1016/j.cell.2017.11.025
21. Espi M, Koppe L, Fouque D, Thaunat O. Chronic kidney disease-associated immune dysfunctions: impact of protein-bound uremic retention solutes on immune cells. Toxins (Basel). 2020;12(5):300. doi:10.3390/toxins12050300
22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001
Article available in :
Volume 4, Issue 2, 2026
Page : 28-33
https://doi.org/10.51271/ICJIM-0072
Article Information
Received : 15 Mar 2026
Accepted : 20 Nis 2026
Published : 26 May 2026
Corresponding Author :

Funda Bulut Arıkan: Department of Physiology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkiye

[email protected]
Citation : Bulut Arıkan F, Öztürk H. Assessment of systemic inflammatory and immune biomarkers and alterations in calcium and parathyroid hormone in hemodialysis patients with type 2 diabetes mellitus. Intercont J Int Med. 2026;4(2):28-33. doi:10.51271/ICJIM-0072

Read: 61
Download : 38
Cited: 0
_Footer